Note 4 - Acquisitions (Tables)

12 Months Ended

Jun. 30, 2020

	B-MoGen Biotechnologies		Exosome Diagnostics		Quad Technologies		Trevigen		Atlanta Biologicals		Eurocell Diagnostics
Current assets, net of cash	$	504	$	2,611	$	36	$	1,662	$	15,722	$	512
Equipment and other long-term assets		269		2,212		228		53		4,901		188
Intangible assets:
Developed technology		14,000		105,000		12,256		5,100		23,000		-
Trade name		-		58,000		-		160		2,300		-
Customer relationships		400		2,300		-		260		3,600		6,272
Goodwill		16,131		105,362		14,481		5,991		10,195		2,910
Total assets acquired		31,304		275,485		27,001		13,226		59,718		9,882

Liabilities		211		3,716		296		387		90		483
Deferred income taxes, net		3,051		16,346		943		2,195		8,354		2,070
Net assets acquired	$	28,042	$	255,423	$	25,762	$	10,644	$	51,274	$	7,329

Cash paid, net of cash acquired		17,448		251,623		20,462	$	10,644	$	51,274	$	5,933
Consideration payable		5,500		-		-		-		-		1,396
Contingent consideration payable		5,094		3,800		5,300		-		-		-
Net assets acquired	$	28,042	$	255,423	$	25,762	$	10,644	$	51,274	$	7,329